By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...
The addition of apalutamide to androgen deprivation therapy before and after surgery improved outcomes among men with ...
SurvivorNet on MSN
ASCO 2026: A major prostate cancer trial shows drug can keep high-risk disease from returning for longer
Data from the PROTEUS trial showed that adding a hormone-blocking pill called apalutamide to standard hormone therapy, both ...
MedPage Today on MSN
Practice-Changing Trial in Prostate Cancer Shows Benefits of Perioperative Therapy
ADT plus apalutamide before and after surgery significantly improved metastasis-free survi ...
Stories by SWNS on MSN
Prostate cancer treatment breakthrough could boost survival rates
A breakthrough in treating an aggressive form of prostate cancer could boost survival rates, according to new research.
Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...
Johnson & Johnson's prostate cancer drug Erleada, reportedly used alongside standard home-blocking therapy before and after ...
New research suggests that men who take multivitamins after being diagnosed with prostate cancer may have a lower risk of cancer recurrence. In the overall study group, current multivitamin users ...
The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...
Beyond the physical, a prostate cancer diagnosis carries significant emotional weight. Understanding this spectrum of ...
Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results